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Abstract
Background: Knockout mice with a deletion of p53 spontaneously develop thymic lymphomas.
Two cell lines (SM5 and SM7), established from two independent tumours, exhibited about fifty to
seventy two-fold differentially expressed proteins compared to wild type thymocytes by two-
dimensional gel electrophoresis (2D-PAGE).
Results: Protein spots excised from 2D-PAGE gels, were subjected to in-gel tryptic digestion and
identified by liquid chromatography – tandem mass spectrometry. A total of 47 protein spots were
identified. Immunological verification was performed for several of the differentially regulated
proteins where suitable antibodies could be obtained. Functional annotation clustering revealed
similarities as well as differences between the tumours. Twelve proteins that changed similarly in
both tumours included up-regulation of rho GDP-dissociation inhibitor 2, proteasome subunit α
type 3, transforming acidic coiled-coil containing protein 3, mitochondrial ornithine
aminotransferase and epidermal fatty acid binding protein and down-regulation of adenylosuccinate
synthetase, tubulin β-3 chain, a 25 kDa actin fragment, proteasome subunit β type 9, cofilin-1 and
glia maturation factor γ.
Conclusion:  Some of the commonly differentially expressed proteins are also differentially
expressed in other tumours and may be putative diagnostic and/or prognostic markers for
lymphomas.
Background
The p53 protein is a ubiquitous transcription factor that is
normally expressed at very low levels. In a majority of
spontaneous virally- or chemically-transformed tumours,
however, p53 protein expression increased. Single nucle-
otide mutations may result in transcription/translation of
p53 protein without transcriptional nuclear activity. Con-
sequently, mutated p53 protein accumulates in the cyto-
plasm where it is proteolytically fragmented. p53-derived
peptides are presented by the MHC class I molecules to
the immune system thereby functioning as potential
tumour rejection epitopes [1].
Functionally, p53 protein halts proliferating cells in the
G1 phase, where DNA repair occurs. In addition, p53 pre-
vents mutations in newly synthesized DNA [2-6]. Individ-
uals genetically deficient in p53, due to mutations or gene
deletion, are more susceptible to the development of
spontaneous tumours [5-7]. These data are consistent
with the high frequency of tumours, in particular thymic
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lymphomas, observed in p53-/- mice from the 12th week
of age [8].
Previously, we have analyzed transcript [8,9] and protein
profiles [10] of wild type mice thymocytes and compared
these with corresponding profiles of two independently
established thymic lymphoma cell lines, SM5 and SM7.
These cell lines spontaneously arose in p53 deleted knock-
out mice. Based upon 2D-PAGE differential analysis, we
identified significant changes in two protein spots (in p53
deleted cells) before tumour formation. The vast majority
of changes, however, occurred after tumour formation.
The SM5 cell line exhibited about seventy protein spot
changes while SM7 displayed about fifty spot changes
[10].
The aim of the present study was to establish the identity
of these tumor-associated differentially expressed pro-
teins. Using in-gel tryptic digestion and liquid chromatog-
raphy – electrospray ionization – tandem mass
spectrometry [11] we here report the identification of 47
of these protein spots.
Results
Differentially regulated proteins in thymic lymphomas
Figs. 1 and 2 display the gel localization of the proteins
identified in the present study. Twelve protein spots, dif-
ferentially expressed in both tumour cell lines (i.e. SM5
and SM7) are labelled using white numbering. Protein
spots that were uniquely differentially expressed in SM5
or SM7 cells are labelled using black numbering. Protein
identifications are listed in Tables 1, 2 and 3. Of the 47
identified spots 5, i.e. 472, 521, 707/730, 1216 and 1470
were ambiguously determined, since more than one pro-
tein were present in each spot. Thus, for these 5 spots it
could not be unequivocally determined which of the pro-
teins that were differentially expressed. Western blotting
was used to verify several of the changes seen.
Commonly differentially regulated proteins
The commonly regulated proteins are given in Table 1. We
identified up-regulation of rho GDP-dissociation inhibi-
tor 2 (1236), proteasome subunit α type 3 (1062), trans-
forming acidic coiled-coil containing protein 3 (131),
mitochondrial ornithine aminotransferase (653) and epi-
dermal fatty acid binding protein (1468).
Two-dimensional gels of wt thymocytes (A) and of SM5 cells from a spontaneous derived tumour (B) Figure 1
Two-dimensional gels of wt thymocytes (A) and of SM5 cells from a spontaneous derived tumour (B). Identified proteins that 
change more than two-fold between wt thymocytes and the SM5 tumour cells are shown based upon previously detected dif-
ferentially expressed protein spots [10]. Up-regulated proteins are shown with white arrows and down-regulated proteins 
with black arrows. Proteins that change similarly in the SM5 and SM7 tumour cells are indicated with white numbers. The iden-
tified proteins are listed in Tables 1 and 2. For alignment purposes the Canvas program was used for mutual adjustment of gels.Proteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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Among the down regulated proteins, we identified adeny-
losuccinate synthetase (622), tubulin β-3 chain (830/
845), a 25 kDa actin fragment (1123), proteasome subu-
nit β type 9 (1284), basic cofilin-1 variant (1357), acidic
cofilin-1 variant (1363/1367) and glia maturation factor
γ, (1382).
Uniquely differentially regulated proteins
Tables 2 and 3 show the obtained peptides from uniquely
regulated proteins. Unambiguously identified up-regu-
lated proteins in tumour cells SM5 included: vinculin, ser-
ine/threonine-protein phosphatase 2A 65 kDa regulatory
subunit A α isoform, prolyl 4-hydroxylase α-1 subunit, α
enolase, ERC-55, eukaryotic translation initiation factor 3
subunit 4, eukaryotic translation initiation factor 2 subu-
nit 1, triosephosphate isomerase, nucleoside diphosphate
kinase B and in tumour cells SM7: 40 kDa peptidyl-prolyl
cis-trans isomerase, acyl-protein thioesterase 1, and nudC
domain-containing protein 2. Spots 298, 300, 302, 309
and 311 contained bovine albumin while spot 308 con-
tained bovine α 2HS-glycoportein or fetuin. Spots 521,
472 and 1470 contained more than one protein.
Unambiguously identified down-regulated proteins in
tumour cells SM5 included: poly(rC)-binding protein 1,
proteasome inhibitor PI31 subunit, histone H4, ATP syn-
thase α chain and in the SM7 tumour cell line: coronin-
1A, adenosine deaminase, heterogeneous nuclear ribonu-
cleoprotein A/B, 4-hydroxyphenyl puruvate dioxygenase,
eukaryotic translation initiation factor 3 subunit 2, perox-
iredoxin-2, ADP-ribosylation factor 1, ubiquitin-conju-
gating enzyme E2 N, actin-like protein 3 and transforming
protein RhoA. Spots 707/730 and 1216 contained more
than one protein.
Immunological verification of differential regulation
To independently confirm 2D-PAGE data, 1D Western
Blot analysis was used to assess the differential expression
of selected protein immunoreactive. Ideally, a single
strong band on a Western blot reflects an antibody pos-
sessing high affinity with specific reaction against the anti-
gen. The data obtained by Western Blot analysis is
presented in Fig. 3.
Fig. 3A depicts Western blot analysis for three commonly
regulated antigens: i.e. epidermal fatty acid binding pro-
tein (FABPE), proteasome subunit β type 9 (PSB9) and
cofilin-1 (COF1). Each produced strong bands in the cells
where the proteins were present in high amounts. Further-
more the data are consistent with and confirm 2D-PAGE
Two-dimensional gels of wt thymocytes (A) and of SM7 cells from a spontaneous derived tumour (B) Figure 2
Two-dimensional gels of wt thymocytes (A) and of SM7 cells from a spontaneous derived tumour (B). Identified proteins that 
change more than two-fold between wt thymocytes and the SM7 tumour cells are shown based upon previously detected dif-
ferentially expressed protein spots [10]. Up-regulated proteins are shown with white arrows and down-regulated proteins 
with black arrows. Proteins that change similarly in the SM5 and SM7 tumour cells are indicated with white numbers. The iden-
tified proteins are listed in Tables 1 and 3. For alignment purposes the Canvas program was used for mutual adjustment of gels.Proteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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Table 1: Differentially regulated proteins commonly found in two different tumours, SM5 and SM7
Protein Identification Peptide sequence Charge Mascot Score Mr (Da) pI SM5 versus Wta SM7 versus Wtb
1236 Rho GDP-
dissociation inhibitor 
2/Ly-GDI 
GDIS_MOUSE
LNYKPPPQK 
(20–28)
2 116 21,754 6.81 Up Up
TLLGDVPVVADP
TVPNVTVTR 
(49–69)
2
YVQHTYR 
(123–129)
2
1062 Proteasome subunit 
α type 3 
PSA3_MOUSE
SSIGTGYDLSASTF
SPDGR (1–19) 
(Acetyl N-term)
2 112 27,861 5.37 Up Up
AVENSSTAIGIR 
(29–40)
2
131 Transforming acidic 
coiled-coil containing 
protein 3/ARNT-
interacting protein 
TACC3_MOUSE
GLLPAEPIVDVLK 
(416–428)
2 31* 88,566 4.04 Up Up
AQAEVLALQASL
R (582–594)
2
653 Ornithine 
aminotransferase, 
mitochondrial 
OAT_MOUSE
TEQGPPSSEYIFER 
(33–46)
2 147 43,842 6.56 Up Up
LFNYNK 
(130–135)
2
LPSDVVTSVR 
(363–372)
2
ESVEIINK 
(427–434)
2
1468 Fatty acid binding 
protein, epidermal 
FABPE_MOUSE
FDETTADGR 
(72–80)
2 66 14,264 6.62 Up Up
622 Adenylosuccinate 
synthetase 
PURA2_MOUSE
VVDLLAQDADIV
CR (46–59)
2 140 45,185 6.95 Up Up
ELPVNAQNYVR 
(420–430)
2
FIEDELQIPVK 
(431–441)
2
830/845 Tubulin β-3 chain 
TBBX_MOUSEc
AILVDLEPGTMDS
VR (63–77)
2 36 36,980/36,445 6.26/6.25 Up Up
1123 Actin (C-terminal) 
ACTX_MOUSEd
DLTDYLMK 
(184–191)
2 43 25,609 5.70 Down Down
EITALAPSTMK 
(316–326)
2
1284 Proteasome subunit 
β type 9/LMP-2d 
PSB9_MOUSE
VSAGTAVVNR 
(40–49)
2 129 19,837 4.42 Down Down
FTTDAITLAMNR 
(174–185)
2
VILGDELPK 
(207–215)
2
1357 Cofilin-1 
COF1_MOUSE
YALYDATYETK 
(81–91)
2 65/65 17,159 7.16 Down Down
1363/1367 Cofilin-1 
COF1_MOUSE
YALYDATYETK 
(81–91)
2 20** 17,199 6.38 Down Down
1382 Glia maturation 
factor γ 
GMFG_MOUSE
FVVYSYK (68–74) 2 117/75 16,626 5.56 Down Down
LVQTAELTK 
(111–119)
2Proteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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data. That is, that FABPE is more than 2-fold up-regulated
in both of the tumour cells and that PSB9 and COF1 are
both more than 2-fold down-regulated in tumour cells.
Fig. 3B and 3C depict Western blot data that verifies the
differential regulation of selected uniquely regulated pro-
teins. That is, eukaryotic translation initiation factor 3
subunit 4 (IF34) and triosephosphate isomerase (TPIS)
were found to be more than 2-fold up-regulated in the
SM5 cell line but in fact also in the SM7 cell line. Simi-
larly, down-regulation in tumour cells SM7 was con-
firmed in case of the proteins coronin-1A (COR1A, 10-
fold), heterogeneous nuclear ribonucleoprotein A/B
(ROAA, 9-fold), peroxiredoxin-2 (PRDX2, 1.5-fold),
ubiquitin-conjugating enzyme E2 N (UBE2N, >10-fold)
and actin-like protein 3 (ARP3, 3.1-fold). All of these pro-
teins were also down-regulated in the tumour SM5.
Based on Western blots data, 2 of the 11 proteins did not
display concordance with 2D-PAGE data, i.e. serine/thre-
onine-protein phsophatase 2A 65 kDa regulatory subunit
A α isoform (2AAA) and ADP-ribosylation factor (ARF).
In case of ADP-ribosylation factor, the apparent discrep-
ancy between Western and 2D-PAGE data may be due to
the fact that six isoforms are known of this protein [12]. It
is highly unlikely that the six isoforms migrate in the same
spot on the 2D gel. Generally, the 2D gel will be able to
distinguish the isoforms as seen with cofilin-1 (1357 and
1363) and coronin-1A (453, 460, and 467) although the
peptides obtained by MS do not contain sufficient infor-
mation to determine which of the variants 1 to 5 is iden-
tified. Only variant 6 can be ruled out. The 1D Western
blot, however, generally recognize all the isoforms in one
band as seen with cofilin-1 and coronin-1A. The changed
expression level of one isoform determined by 2D-PAGE
may then be obscured if other isoforms do not change
similarly or change in the opposite direction giving no
major overall change of the different isoforms taken as a
whole on the Western blot. The same may be true for ser-
ine/threonine-protein phsophatase 2A 65 kDa regulatory
subunit A α isoform (2AAA) [13]. Thus, generally our
study shows, as others [14,15], that the differential regu-
lation of the proteins seen by 2D-PAGE could be quanti-
tatively confirmed by Western blotting in 8 of 11 cases.
These eight were epidermal fatty acid binding protein
(FABPE), proteasome subunit β type 9 (PSB9), cofilin-1
(COF1), eukaryotic translation initiation factor 3 subunit
4 (IF34), triosephsophate isomerase (TPIS), coronin-1A
(COR1A), heterogeneous nuclear ribonucleoprotein A/B
(ROAA) and ubiquitin-conjugating enzyme E2 N
(UBE2N).
With respect to the five spots containing more than one
protein we tried antibodies against UV excision repair pro-
tein RAD23 homolog B (472), galectin-7 (1470) and Ras
related protein Rab-11A (spot 1216). Unfortunately, the
quality of the results was insufficient for firm conclusions.
Discussion
Previously, we have detected differentially-expressed pro-
teins in spontaneously formed tumours in p53 knockout
mice [10]. Changes in the expression of two of the pro-
teins identified preceded tumour formation. In the vast
majority, however, changes in expression coincided with
or paralleled tumour formation, with about seventy pro-
tein spots changing in the SM5 cell line while about fifty
spot changes were found in the SM7 cell line. The aim of
this study was to further characterise and identify,
tumour-associated changes in protein expression.
A subset of the proteins were commonly regulated, chang-
ing at least two-fold by 2D-PAGE in both tumours while a
number of proteins, originally detected in one of the
tumours also could be found to be differentially regulated
in the other tumour as detected by immunodetection.
Such differentially expressed proteins may represent pro-
teins that are of general importance in order to under-
stand the transformation process initiated by the deletion
of p53. Furthermore, some of them might be suitable as
diagnostic or prognostic markers for lymphomas or other
tumours that include deletion of p53. Several genes
responsive to elevated levels of p53 have been identified
[16-18]. In the p53 deleted cells we did not detect differ-
ential regulation of direct downstream targets of p53
within the major pathways including cell cycle arrest,
DNA repair, apoptosis, angiogenesis or cellular stress
response. We did observe down regulation of a C-terminal
actin fragment in both cell lines (spot 1123). α actin has
been reported to be a transcriptional target of p53 [19]
and down-regulation could be due to a decreased expres-
TTDDLTETWLK 
(125–135)
2
The significance level for the peptides given were p < 0.05 when searching in the total database except the protein indicated with (*) that was 
significant when searching in the mouse part of the database and the peptide given with (**) that was not significant. The non-significant peptide 
(1363/1367) was included because of the similarity to the significant peptide 1357.
a Up, protein that is up-regulated in SM5 cells versus wt. Down, protein that is down-regulated in SM5 cells versus wt.
b Up, protein that is up-regulated in SM7 cells versus wt. Down, protein that is down-regulated in SM7 cells versus wt.
c X is 2A, 2B, 3 or 5
d X is A, B, C, G, H or S
Table 1: Differentially regulated proteins commonly found in two different tumours, SM5 and SM7 (Continued)Proteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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Table 2: Differentially regulated proteins in the SM5 tumour
Protein Identification Sequence Charge Mascot Score Mr pI SM5 versus wta
79 Vinculin VINC_MOUSE SLGEIAALTSK 
(433–443)
2 29* 101,649 6.64 Up
298/300/302/309/
311
Albumin ALBU_BOVIN LVNELTEFAK 
(66–75)
2 569/623/943/164/
505
64.8–65.6 (kDa) 5.92–6.37 Up
SLHTLFGDELCK 
(89–100)
2
LKPDPNTLCDEF
KADEK (139–155)
3
YLYEIAR 
(161–167)
2
LSQKFPK 
(242–248)
2
AEFVEVTK 
(249–256)
2
YICDNQDTISSK 
(286–297)
2
SHCIAEVEK 
(310–318)
2
EYEATLEECCAK 
(375–386)
2
HLVDEPQNLIK 
(402–412)
2
LGEYGFQNALIVR 
(421–433)
2
KVPQVSTPTLVEV
SR (437–451)
2/3
VPQVSTPTLVEVS
R (438–451)
2
LCVLHEK 
(483–489)
2
CCTESLVNR 
(499–507)
2
QTALVELLK 
(549–557)
2
TVMENFVAFVDK 
(569–580)
2
CCAADDKEACF
AVEGPK 
(581–597)
3
308 α-2HS-glycoprotein 
FETUA_BOVIN
HTLNQIDSVK 
(58–67)
2 519 63.2 (kDa) 3.58 Up
QQTQHAVEGDC
DIHVLK 
(104–120)
3
QDGQFSVLFTK 
(121–131)
2
CDSSPDSAEDVR 
(132–143)
2
CDSSPDSAEDVR
K (132–144)
2/3
EVVDPTKCNLLA
EK (212–225)
3
CNLLAEK 
(219–225)
2
ALGGEDVR 
(238–245)
2
TPIVGQPSIPGGPV
R (334–348)
2
353 Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A α 
isoform 2AAA_MOUSE
LAGGDWFTSR 
(134–143)
2 138/70 61,309 4.97 UpProteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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MAGDPVANVR 
(527–536)
2
LTQDQDVDVK 
(566–575)
2
385 Prolyl 4-hydroxylase α-1 
subunit P4HA1_MOUSE
LQDTYNLDTNTI
SK (137–150)
2 61/140 59,705 6.06 Up
RPCTLSELE 
(526–534)
2
521 Ig α-1 chain C region 
IGHA1_HUMAN/
Lysozyme C 
LYSC_HUMAN/Deleted 
in malignant brain tumours 
1 protein 
DMBT1_HUMAN
DASGVTFTWTPS
SGK (154–168)
2 181 50,620 6.15 Up
WLQGSQELPR 
(264–273)
2
QEPSQGTTTFAV
TSILR (283–299)/
2
STDYGIFQINSR 
(69–80)/
28 7
FGQGSGPIVLDD
VR (73–86)
27 7
584 α-enolase ENOA_Mouse GNPTVEVDLYTA
K (15–27)
2 241 47,174 6.83 Up
AAVPSGASTGIYE
ALELR (32–49)
2
YITPDQLADLYK 
(269–280)
2
VNQIGSVTESLQA
CK (343–357)
2
YNQILR 
(406–411)
2
IEEELGSK 
(412–419)
2
592 α-enolase ENOA_Mouse AAVPSGASTGIYE
ALELR (32–49)
2 179 46,971 7.03 Up
YITPDQLADLYK 
(269–280)
2
DATNVGDEGGF
APNILENK 
(202–220)
2
641 ERC-55 RCN2_MOUSE VIDFDENTALDD
TEEGSFR 
(133–151)
2 31* 44,221 3.51 Up
650 Eukaryotic translation 
initiation factor 3 subunit 
4 IF34_MOUSE
VTNLSEDTR 
(243–251)
2 53 44,126 5.83 Up
814 Eukaryotic translation 
initiation factor 2 subunit 
1 IF2A_MOUSE
VVTDTDETELAR 
(276–287)
2 81 37,463 5.12 Up
1134 Triosephosphate 
isomerase TPIS_MOUSE
VVLAYEPVWAIG
TGK (159–173)b
2 37 25,173 8.28 Up
1384 Nucleoside diphosphate 
kinase B NDKB_MOUSE
GDFCIQVGR 
(91–99)
2 46 16,433 8.66 Up
472 UV excision repair protein 
RAD23 homolog B 
RD23B_MOUSE/
Endoplasmin 
ENPL_MOUSE
IDIDPEETVK 
(15–24)
2 51 53,046 4.41 Up
ASFNNPDR (213–
220)/
2
SILFVPTSAPR 
(305–315)
28 3
GVVDSDDLPLNV
SR (355–368)
2
Table 2: Differentially regulated proteins in the SM5 tumour (Continued)Proteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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707/730 Actin ACTB_MOUSE/
UBA/UBX 33.3 kDa 
protein U33K_MOUSE
AGFAGDDAPR 
(1–10)
2 156 41,158/40,562 5.19/5.23 Down
GYSFTTTAER 
(179–188)
2
SYELPDGQVITVG
NER (218–233)/
LPDGTSLTQTFR 
(220–231)
27 4
761 Poly(rC)-binding protein 1 
PCBP1_MOUSE
INISEGNCPER 
(47–57)
2 110 39,587 7.46 Down
IANPVEGSSGR 
(315–325)
2
972 Proteasome inhibitor PI31 
subunit PSMF1_MOUSE
VLIDPSSGLPNR 
(220–231)
2 43 31,039 4.68 Down
997 Histone H4 H4_MOUSE ISGLIYEETR 
(46–55)
2 32* 30,490 7.22 Down
1031 ATP synthase α chain, 
mitochondrial 
ATPA_MOUSE
VLSIGDGIAR 
(74–83)
2 86 29,286 9.32 Down
VVDALGNAIDGK 
(150–161)
2
The significance level for the peptides given were p < 0.05 when searching in the total database except the peptides indicated with (*) that were 
significant when searching in the mouse part of the database.
a Up, protein that is up-regulated in SM5 cells versus wt. Down, protein that is down-regulated in SM5 cells versus wt.
b The peptide was not given as bold in the search, but was similar to a bold peptide in various other species except that L was exchanged with I.
Table 2: Differentially regulated proteins in the SM5 tumour (Continued)
sion of the actin gene. The observation might also be
explained by a decrease in the cleavage of the actin pro-
tein.
Functional annotation clustering of differentially regulated 
proteins
Each of the identified proteins may be functionally classi-
fied based on the Gene Ontology annotation system [20].
This system is a structured, organized vocabulary that sys-
tematically describes each protein with respect to cellular
component, biological process and molecular function.
By using the DAVID Bioinformatics Resource [21] we per-
formed a functional annotation clustering of the proteins
involved in the transformation. With the highest classifi-
cation stringency, we found seven clusters for SM5 and
eleven clusters for SM7 as shown in Tables 4 and 5. The
clusters are listed with the most enriched at top. For exam-
ple, the 3 proteins PURA2, NKDB and ATPA of the 24 pro-
teins analyzed with the cell line SM5 belong to the cluster
purine nucleotide biosynthetic process. The p value at
0.0039 indicates that this function is significantly over
represented among the 24 proteins analyzed. Similarly,
proteins involved in cellular process, glucose metabolic
process, translation factor activity (nucleic acid binding)
and the actin cytoskeleton were all significant. Some of
the proteins belong to more than one category since they
possess multiple functions. The SM7 cell line was in some
respects similar to SM5 but in other respects different
since functions that were over represented by the transfor-
mation included GTP binding, cytoskeleton, cellular proc-
ess, ubiquitin-dependent protein catabolic process,
intracellular transport and GTPase activity. The partly dif-
ferent functions of the two cells may partly explain the dif-
ferent physiology of the two cell lines where SM7 is 3–5
times more tumourigenic compared with SM5 [10].
Differentially regulated cancer related proteins
Oncogenesis is not a term within the Gene Ontology clas-
sification. However, some of the commonly regulated
proteins are known from other studies also to be involved
in carcinogenesis and will be briefly described.
Rho GDP-dissociation inhibitor 2 (1236)
Rho GDP-dissociation inhibitor 2 is preferentially
expressed in lymphocytes [22] and found to be up-regu-
lated in the two tumour cells analyzed. Recently, the pro-
tein was also found to be up-regulated in oral squamous
cell carcinoma whereas the mRNA level was only very
slightly up-regulated [23]. The Rho GDP-dissociation
inhibitors play a role in the modulation of the activity of
the Rho proteins. Overexpression leads to rounding up of
cells and loss of stress fibers and focal contact sides [24].
Transforming acidic coiled-coil containing protein 3 (TACC3) (131)
TACC3 was found to be up-regulated in both tumour cell
lines. The transcript has been previously found to be
strongly present in testis, at low level in human thymus
and very low levels in a number of tissues of the immune
system while several cancer cell lines express up-regulated
levels of the transcript [25]. Recently, Jung et al. have
found TACC3 protein expression to be a prognostic
marker of non-small cell lung carcinoma where 14.8% ofProteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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Table 3: Differentially regulated proteins in the SM7 tumour
Protein Identification Sequence Charge Mascot score Mr pI SM7 versus wta
777 40 kDa peptidyl-prolyl cis-trans isomerase 
PPID_MOUSE
TLENVEVNGEKPAK 
(160–173)
2 66 39,459 5.23 Up
ILLISEDLK (218–226) 2
EYDQALADLK (321–330) 3
1124 Acyl-protein thioesterase 1 LYPA1-MOUSE ASFQGPINSANR (150–162) 2 54 25,565 5.88 Up
1400 NudC domain- containing protein 2 
NUDC2_MOUSE
AQDIQCGLQSR (40–50) 2 57 16,128 4.76 Up
1470 40S ribosomal protein S12 RS12_MOUSE/
Galectin-7LEG7_MOUSE
AEEGIAAGGVMDVNTALQEV
LK (1–22) (Acetyl N-term)
2 125 14,314 7.83 Up
LGEWVGLCK (84–92)/ 2
LTDSEVVFNTK (54–64) 2 81
467 Coronin-1A COR1A_MOUSE VSQTTWDSGFCAVNPK 
(30–45)
2 267 54,369 6.95 Down
DGALICTSCR (187–196) 2
ILTTGFSR (234–241) 2
QVALWDTK (246–253) 2
DAGPLLISLK (384–393) 2
ATPEPSGTPSSDTVSR 
(417–432)
2
453 Coronin-1A COR1A_MOUSE ADQCYEDVR (21–29) 2 123 54,503 6.59 Down
VSQTTWDSGFCAVNPK 
(30–45)
2
DAGPLLISLK (384–393) 2
460 Coronin-1A COR1A_MOUSE VSQTTWDSGFCAVNPK 
(30–45)
2 185 54,503 6.74 Down
ILTTGFSR (234–241) 2
DAGPLLISLK (384–393) 2
ATPEPSGTPSSDTVSR 
(417–432)
2
700 Adenosine deaminase ADA_MOUSE AQTPAFNKPK 
(1–10) (Acetyl N-term)
2 130/188 41,426 5.83 Down
GIALPADTVEELR (34–46) 2
IAYEFVEMK (81–89) 2
EGVVYVEVR (93–101) 2
ANYSLNTDDPLIFK (288–301) 2
727 Heterogeneous nuclear ribonucleoprotein 
A/B ROAA_MOUSE
IFVGGLNPEATEEK (161–174) 2 15** 40,430 6.69 Down
823 4-hydroxyphenyl puruvate dioxygenase 
HPPD_MOUSE
TEDIITAIR (270–278) 2 28* 36,980 6.66 Down
835 Eukaryotic translation initiation factor 3 
subunit 2 IF32_MOUSE
SYSSGGEDGYVR (299–310) 2 56/51 36,622 5.89 Down
1216 Ras-related protein Rab-11B 
RB11B_MOUSE/ATP-dependent RNA 
helicase DDX39 DDX39_MOUSE
GAVGALLVYDIAK (82–94) 2 65 22,463 5.87 Down
NILTEIYR (166–173)/ 2
ILVATNLFGR (338–348) 2 90
1243 Peroxiredoxin-2 PRDX2_MOUSE GLFIIDAK (128–135) 2 106 21,457 4.76 Down
QITVNDLPVGR (140–150) 2
1364 ADP-ribosylation factor 1 ARFX_MOUSEb ILMVGLDAAGK (19–29) 2 50 17,059 6.80 Down
1430 Ubiquitin-conjugating enzyme E2 N 
UBE2N_MOUSE
LLAEPVPGIK (15–24) 2 107/128 15,088 6.53 Down
TNEAQAIETAR (131–141) 2
599 Actin-like protein 3 ARP3_MOUSE YSYVCPDLVK (231–240) 2 97 46,669 6.25 Down
NIVLSGGSTMFR (318–329) 2
LSEELSGGR (349–357) 2
DYEEIGPSICR (399–409) 2
740 Heterogeneous nuclear ribonucleoprotein 
A/B ROAA_MOUSE
IFVGGLNPEATEEK (161–174) 2 113 40,104 7.11 Down
EVYQQQQYGSGGR 
(238–250)
2Proteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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1184 Transforming protein RhoA 
RHOA_MOUSE
LVIVGDGACGK (8–18) 2 79 23,410 6.82 Down
IGAFGYMECSAK (151–162) 2
The significance level for the peptides given were p < 0.05 when searching in the total database except the peptide indicated with (*) that was 
significant when searching in the mouse part of the database and the peptide given with (**) that was not significant. The non-significant peptide 
(727) was included because of the similarity to the significant peptide 740.
a Up, protein that is up-regulated in SM7 cells versus wt. Down, protein that is down-regulated in SM7 cells versus wt.
b X is 1, 2, 3, 4 or 5.
Table 3: Differentially regulated proteins in the SM7 tumour (Continued)
Western blots of wt thymocytes and thymocytes from two spontaneously arising tumours, SM5 and SM7 Figure 3
Western blots of wt thymocytes and thymocytes from two spontaneously arising tumours, SM5 and SM7. Equal amounts of 
protein were added to the lanes used for analysis of one antibody, either 5, 10 or 30 mg per lane. The bands were scanned and 
quantitated using the Quantity One program. The measured changes are indicated below the blot with wild type arbitrarily set 
to 1.0. Proteins that, from 2D-PAGE analysis, were found to change at least 2-fold are given in (A) for the commonly regulated 
and in (B) and (C) for the individually changed in SM5 and SM7, respectively.
the tumours expressed high levels [26]. The authors also
found TACC3 expression to be correlated with p53 expres-
sion and that patients with high expression of both pro-
teins had significantly poorer prognosis than patients
with low-level expression of both [26].
Ornithine aminotransferase (653)
Ornithine aminotransferase (OAT) was found to be up-
regulated in both tumour cell lines. Previously, it has been
found by subtractive hybridisation that the transcript of
OAT is up-regulated in hepatocellular carcinomas [27].Proteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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Table 4: Functional annotation clustering of proteins involved in the transformation of tumour cell line SM5
Functional annotation clusteringa Function Proteins involved P value
Purine nucleotide biosynthetic process The chemical reactions and pathways resulting in the formation of a 
purine nucleotide, a compound consisting of nucleoside (a purine 
base linked to a deoxyribose or ribose sugar) esterified with a 
phosphate moiety at either the 3' or 5'-hydroxyl group of its glycose 
moiety.
PURA2 0.0039
NKDB
ATPA
Cellular process Processes that are carried out at the cellular level, but are not 
necessarily restricted to a single cell. For example, cell 
communication occurs among more than one cell, but occurs at the 
cellular level.
H4 0.047
PSB9
TBB3
VINC
IF34
PURA2
ENOA
IF2A
ATPA
P4HA1
FABPE
COF1
TPIS
TACC3
PSA3
NDKB
ACTB
PCBP1
OAT
Glucose metabolic process The chemical reactions and pathways involving glucose, the 
aldohexose gluco-hexose. D-glucose is dextrorotatory and is 
sometimes known as dextrose; it is an important source of energy for 
living organisms and is found free as well as combined in homo- and 
hetero-oligosaccharides and polysaccharides.
TPIS 0.006
ENOA
FABPE
Translation factor activity, nucleic acid binding Functions during translation by binding nucleic acids during 
polypeptide synthesis at the ribosome.
IF34 0.011
IF2A
PCBP1
Actin cytoskeleton The part of the cytoskeleton (the internal framework of a cell) 
composed of actin and associated proteins. Includes actin 
cytoskeleton-associated complexes.
COF1 0.022
VINC
ACTB
ATP binding Interacting selectively with ATP, adenosine 5'-triphosphate, a 
universally important coenzyme and enzyme regulator.
NDKB 0.48
ATPA
ACTB
Regulation of cellular process Any process that modulates the frequency, rate or extent of cellular 
processes, those that are carried out at the cellular level, but are not 
necessarily restricted to a single cell. For example, cell 
communication occurs among more than one cell, but occurs at the 
cellular level.
COF1 0.76
VINC
TACC3
IF2A
a For each cluster is listed the GO term possessing the highest enrichment score using the DAVID bioinformatics Resource [21]. In some cases this 
GO term was obsolete in which case the nearest well defined term was listed.Proteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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Table 5: Functional annotation clustering of proteins involved in the transformation of tumour cell line SM7
Functional annotation clusteringa Function Proteins involved P value
GTP binding Interacting selectively with GTP, guanosine triphosphate. TBB3 0.0073
ARF1
PURA2
RHOA
Cytoskeleton Any of the various filamentous elements that form the internal 
framework of cells, and typically remain after treatment of the cells 
with mild detergent to remove membrane constituents and soluble 
components of the cytoplasm. The term embraces intermediate 
filaments, microfilaments, microtubules, the microtrabecular lattice, 
and other structures characterized by a polymeric filamentous nature 
and long-range order within the cell. The various elements of the 
cytoskeleton not only serve in the maintenance of cellular shape but 
also have roles in other cellular functions, including cellular 
movement, cell division, endocytosis, and movement of organelles
COF1 0.0012
TBB3
TACC3
ARP3
RHOA
ACTB
Cellular process Processes that are carried out at the cellular level, but are not 
necessarily restricted to a single cell. For example, cell 
communication occurs among more than one cell, but occurs at the 
cellular level.
PSB9 0.047
TBB3
PURA2
ROAA
PRDX2
ADA
LYPA1
FABPE
IF32
COF1
ARF1
TACC3
HPPD
RHOA
PSA3
PPID
ACTB
UBE2N
OAT
Ubiquitin-dependent protein catabolic process The chemical reactions and pathways resulting in the breakdown of a 
protein or peptide by hydrolysis of its peptide bonds, initiated by the 
covalent attachment of a ubiquitin moiety, or multiple ubiquitin 
moieties, to the protein.
PSB9 0.010
PSA3
UBE2N
Intracellular transport The directed movement of substances within a cell. TBB3 0.042
ARF1
TACC3
RHOA
GTPase activity Catalysis of the reaction: GTP + H2O → GDP + phosphate. TBB3 0.010
ARF1
ROHA
Cellular protein metabolic process The chemical reactions and pathways involving a specific protein, 
rather than of proteins in general, occurring at the level of an 
individual cell. Includes protein modification.
PSB9 0.098
COF1
TBB3
PSA3
PPIDProteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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Epidermal fatty acid binding protein (1468)
E-FABP is a fatty acid binding protein that was originally
found to be up-regulated in psoriatic skin [28]. Recently,
it was found that E-FABP is up-regulated in head and neck
squamous cell carcinomas and a number of carcinoma
cell lines [29]. In addition, it was found that EpCAM, a
tumour associated antigen, up-regulates E-FABP and fur-
thermore that EpCAM is positively correlated with the
grade of dysplasia being a negative prognostic factor for
breast cancer patients [29].
Proteasome subunit   type 9 (LMP2)
The proteasome is a complex structure localized in the
cytosol and composed of several different subunits. Some
of the subunits are constitutively expressed while others,
including LMP2, belong to the facultative subunits that
may exchange with the constitutively expressed subunits
as a result of immune stress [30]. Proteasome subunit β
type 9 was down-regulated in the tumour cells analyzed
here. It has previously been found that LMP2 generally is
down-regulated in several types of tumours such as laryn-
geal squamous cell carcinoma [31], head and neck squa-
mous cell carcinoma [32], renal cell carcinoma [33], as
well as in a number of tumour cell lines including small-
cell lung carcinoma, hepatocellular carcinoma, colon ade-
nocarcinoma and basophilic leukemia [34].
Plasma derived proteins
In SM5 cells we identified two proteins that were mark-
edly present and clearly originated from bovine plasma,
fetuin (308) and albumin (298, 300, 302, 309 and 311).
Both proteins were detected from SM5 cells but were only
vaguely seen in SM7 cells. The likely differences between
the isoforms of BSA are various types of modifications
that may occur, e.g. following oxidation [35]. These mod-
ifications include glycosylations at a number of Lys resi-
dues. Since the cells were treated similarly, it is unlikely
that the presence of them in one of the cell lines is due to
contamination obtained during the preparation of the
cells. Endothelial cells have previously been shown to take
up fetuin [36]. Recently, it was shown that fibroblasts are
also able to perform this internalization and that the
internalization is down-regulated by hypoxia [37]. The
present study indicates that especially transformed thy-
mocytes (SM5) may have gained the ability to perform
this internalisation. We, however, cannot exclude that the
proteins also could adhere to the surface of the cells rather
than being internalized.
Comparison with previous observed changes in mRNA in 
SM7
Using one of the early mouse oncogene arrays, Atlas
mouse array I (Clontech) encompassing 588 oncogenes,
we have previously identified several differentially regu-
lated transcripts in the two tumour cell lines [8,9]. Only a
few overlaps were found between the identified set of pro-
IF32
UBE2N
Intracellular protein transport The directed movement of proteins in a cell, including the movement 
of proteins between specific compartments or structures within a 
cell, such as organelles of a eukaryotic cell.
ARF1 0.094
TACC3
RHOA
Negative regulation of cellular process Any process that stops, prevents or reduces the frequency, rate or 
extent of cellular processes, those that are carried out at the cellular 
level, but are not necessarily restricted to a single cell. For example, 
cell communication occurs among more than one cell, but occurs at 
the cellular level.
TACC3 0.19
RHOA
PRDX2
Regulation of cellular process Any process that modulates the frequency, rate or extent of cellular 
processes, those that are carried out at the cellular level, but are not 
necessarily restricted to a single cell. For example, cell 
communication occurs among more than one cell, but occurs at the 
cellular level.
COF1 0.53
TACC3
RHOA
ROAA
PRDX2
Ion binding Interacting selectively with ions, charged atoms or groups of atoms. PURA2 0.93
HPPD
ADA
a For each cluster is listed the GO term possessing the highest enrichment score using the DAVID bioinformatics Resource [21]. In some cases this 
GO term was obsolete in which case the nearest well defined term was listed.
Table 5: Functional annotation clustering of proteins involved in the transformation of tumour cell line SM7 (Continued)Proteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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teins differentially expressed here and the previously iden-
tified differentially regulated transcripts. These included
nucleoside diphosphate kinase B, UV excision repair pro-
tein RAD23 homolog B, and ubiquitin regulating enzyme
E2.
Conclusion
We detected and identified several proteins, that were dif-
ferentially regulated as a result of transformation follow-
ing deletion of the p53 gene. Immunological verification
of differential regulation was performed in 8 of 11 cases.
Among the two cell types SM5 and SM7 that differed in
their carcinogenic potential, we also found differences in
the functional annotation clustering. A major part of the
commonly regulated set of proteins have previously been
found to be related to several other types of cancers indi-
cating that they may play a role in the transformation
process. Studies will be performed to investigate their
putative role as diagnostic or prognostic biomarkers in
human lymphomas. Biopsies could be histochemically
analyzed using antibodies against the differentially
expressed proteins in order to diagnostically and/or prog-
nostically classify lymphomas. Putative up-regulated pro-
teins might further be analyzed for their presence in the
blood to be used as diagnostic and/or prognostic biomar-
kers.
Methods
Analysis of two-dimensional gels
The performance and analysis of two-dimensional gels
have been described in detail previously [10]. Briefly, sil-
ver stained gels were scanned in the transmissive mode on
a GS-710 Imaging Densitometer (Bio-Rad) using Quan-
tity One. The 16-bit gray scale TIFF files were imported
into Melanie II. Initially, protein spots were automatically
defined and quantified. Spot intensities were expressed as
relative volumes in percentages (%VOL) by integrating
the optical density of each pixel in the spot area (VOL)
and dividing with the sum of volumes of all spots
detected. About 10–12 of the spots were used as land-
marks. One of the gels was selected as reference gel and
used to align and match the other gels. The quality of the
match was critically evaluated and necessary editions and
corrections done manually. Comparisons were performed
between two groups of gels by selecting spots that differed
more than two-fold between the groups. These data were
exported to Excel for further statistical analysis using Stu-
dent's t-test as previously described [10].
Identification of proteins by liquid chromatography-
tandem mass spectrometry (LC-MS/MS)
Protein identification by LC-MS/MS was performed as
previsously described [38]. Briefly, previously run gels
[10] containing protein spots selected for identification
were re-hydrated in water. The cellophane sheets were
peeled off so the protein spots could be excised from the
gels. Proteins were in-gel digested with trypsin. Gel pieces
were first dehydrated in acetonitrile, then dried and pro-
teins reduced for 1 h at 56°C in 10 mM dithiotreitol
(DTT) and 100 mM NH4HCO3. The solution was
exchanged with 55 mM iodoacetamide in 100 mM
NH4HCO3 for 45 min. Then it was washed in 100 mM
NH4HCO3, dehydrated in acetonitrile, rehydrated in 100
mM NH4HCO3, dehydrated in acetonitrile, dried and
swelled in digestion buffer (50 mM NH4HCO3, 5 mM
CaCl2 and 12.5 ng/μl trypsin Gold (mass spectrometry
grade; Promega, Madison, WI, USA). Digestion was per-
formed overnight at 37°C and the peptides were extracted
by 1 change of 20 mM NH4HCO3 and 3 changes of 5%
formic acid in 50% acetonitrile. The sample was finally
dried and the peptides resuspended in 12 μl of buffer A
(water/acetonitrile/formic acid, 97.7/2/0.3, V/V/V). The
peptides were separated on an inert nano LC system com-
posed of a FAMOS micro autosampler, a Switchos micro
column switching module and an Ultimate micro pump
from LC Packings (San Francisco, CA) before MS analysis.
Of the in-gel digested samples 5 μl was preconcentrated
and desalted on a 300 μm inner diameter × 5 mm Nano-
Precolumn (LC Packings) packed with 5 μm C18
PepMap100 material. A 75 μm inner diameter × 15 cm
Nano column packed with 3 μm C18 PepMap100 mate-
rial was used to separate the peptides. Elution from the
column was made with a gradient by mixing decreasing
volumes of buffer A with increasing volumes of buffer B
(water/acetonitrile/formic acid, 9.7/90/0.3, V/V/V). The
peptides were eluted into the nano electrospray ion source
of the quadrupole time-of-flight Q-TOF Ultima mass
spectrometer (Micromass, Manchester, UK). MS survey
scans were acquired using MassLynx 4 SP4 (Waters) at a
rate of 1 per second from m/z 400–2000. The instrument
was operated in a data-dependent MS to MS/MS switching
mode. Doubly, triply and quadruply charged peptide ions
detected in MS survey scans triggered a switch to MS/MS
for obtaining peptide fragmentation spectra with an inter-
val of m/z values 50–2000. Raw data were processed using
ProteinLynx GlobalServer 2.1 (Waters). Processing
parameters were as follows: Background Subtract: Nor-
mal, Background Threshold: 35%, Background Polyno-
mial: 5, Smoothing Type: Savitzky-Golay, Smoothing
Iterations: 2, Smoothing Window: 2 channels, Deisotop-
ing Type: Normal, Deisotoping Threshold: 1%. The proc-
essed data were used to search the total part and the
mouse fraction of the Swiss-Prot database (releases 49.7,
54.0 and 54.4) using the on-line version of the Mascot
MS/MS Ion Search facility (Matrix Science, Ltd., http://
www.matrixscience.com) [39]. Searching was performed
with doubly and triply charged ions with 2 missed cleav-
ages, a peptide tolerance of 20, 50 or 100 ppm, one varia-
ble modification either Carbamidomethyl-C or N-
terminal acetyl and an MS/MS tolerance of 0.05 or 0.08Proteome Science 2008, 6:18 http://www.proteomesci.com/content/6/1/18
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Da. Contaminating peptides, including keratins and
trypsin were disregarded. At least one 'bold red' peptide
was required in the search. Peptides for proteins with
scores giving a less than 5% probability that the observed
match was a random event are reported.
Western blotting
Normal C57BL/6 mice (wt) were purchased from Bom-
holtgaard, Ry, Denmark. The mice were kept under con-
ventional conditions at the animal facility at the Panum
Institute. The thymus was pressed through a metal net and
single cell suspensions were recovered on a foetal calf
serum gradient allowing clumps and debris to settle. By
haemocytometer examination more than 99% of the cells
are lymphoid. Thymocytes were prepared from three mice
and pooled. They were then washed extensively in PBS
and lyophillized. C57BL/6J-Trp53tm1Tyj mice deficient
for the p53 gene were purchased from the Jackson Labo-
ratory, USA. Two spontaneously developing thymic lym-
phomas, SM5 and SM7, were explanted, in vitro cultured,
and established as cell lines growing in RPMI-1640 cul-
ture medium supplemented with 10% fetal calf serum
and 50 μM 2-mercaptoethanol. Cells were washed exten-
sively in PBS, harvested with a rubber police man and
lyophilized. Protein concentration was determined using
a non-interfering assay (NI Protein Assay, Geno Technol-
ogy Inc., St Louis, MO, USA). For 1D gel electrophoresis
equal amounts of proteins (either 5, 10 or 30 μg) from
each of the cell preparations, wt, SM5 and SM7 were
added to each lane of a 10–20% Tris-Glycine gel (Invitro-
gen). After electrophoresis the separated proteins were
transferred to a nitrocellulose membrane. For immunode-
tection, the membrane was incubated overnight at 4°C in
PBS containing 0.05% Tween-20 and 5% skim milk,
washed three times in PBS with Tween-20, and incubated
with the appropriate dilution of the primary antibody for
at least 1 h at room temperature in PBS with Tween-20
and 5% skim milk. After three washes in PBS with Tween-
20 the blot was incubated for 1 h with peroxidase-conju-
gated secondary antibody in PBS with Tween-20. Finally,
after five washes in PBS with Tween-20, the blot was
developed using enhanced chemiluminescence (Amer-
sham Biosciences, Piscataway, NJ, USA). The bands were
visualized on film (Kodak), scanned with a GS-710 Imag-
ing Densitometer from Bio-Rad and the intensities of the
bands were evaluated using the Quantity One software
package.
Several antibodies were obtained from commercial sup-
pliers. The following rabbit antibodies were used: anti-
cofilin (Abcam), dilution 1:10,000 (9 μg/ml); anti-ubiq-
uitin conjugating enzyme E2 N (Calbiochem), dilution
1:10 (50 μg/ml); anti-proteasome 20S LMP2 (Abcam),
dilution 1:100 (1 μg/ml); anti-peroxiredoxin 2 (Abcam),
dilution 1:2,000 (0.5 μg/ml); anti-transforming acidic
coiled coil containing protein 3 (Biolegend), dilution 1:5;
anti-NM23-H1/H2 (Alexis) dilution 1:100 (10 μg/ml);
anti-RAD23B (Abgent), dilution 1:10 (25 μg/ml), anti-
cyclophillin 40 PPID (Abcam), dilution 1:10; anti-galec-
tin 7 (Abcam), dilution 1:30 (33 μg/ml); anti-adenosine
deaminase (ADA) (Nordic Biosite), dilution 1:20; anti-
Rab11a (Nordic Biosite), dilution 1:60 (2 μg/ml); anti-Ly-
GDI (Santa Cruz Biotechnology, INC.), dilution 1:50 (4
μg/ml); anti-serine/threonine protein phosphatase 2a/a
(Sigma), dilution 1:10 (10 μg/ml). The following mouse
antibodies were used: anti-ADP ribosylation factor
(Abcam), dilution 1:50; anti-proteasome 20S α 3
(Abcam), dilution 1:25; anti-Actin like protein 3 (Arp3)
(BD Biosciences Pharmingen), dilution 1:100 (2.5 μg/
ml); anti-hnRNP-A2/B1 (ImmuQuest, Ltd.) dilution
1:500 (2 μg/ml); anti-vinculin (Abcam), dilution 1:10 (1
mg/ml); anti-Rho GDP-dissociation inhibitor 2 (Rho-
GDI2) (Alexis) dilution 1:10 (50 μg/ml). The following
goat antibodies were used: anti-coronin 1 (Everest Bio-
tech), dilution 1:100 (5 μg/ml); anti-FABP5 (R & D Sys-
tems), dilution 1:10 (20 μg/ml); anti-triosephosphate
isomerase (TPI1) (Everest Biotech, Ltd.), dilution 1:1,000
(0.5 μg/ml); anti-eIF3β (Santa Cruz Biotechnology, Inc.),
dilution 1:5 (40 μg/ml). The following chicken antibody
was used: anti-eukaryotic translation initiation factor 3,
subunit 4 δ, 44 kDa (EIF3S4), (GenWay Biotech, Inc.),
dilution 1:1,000 (1 μg/ml). Secondary HRP conjugated
antibodies were purchased from DAKO (Denmark): anti-
rabbit PO217, dilution 1:5,000 (0.26 μg/ml); anti-mouse
PO260, dilution 1:5,000 (0.26 μg/ml); anti-goat, PO449,
dilution 1:5,000 (0.1 μg/ml) and from Abcam (UK) anti-
chicken (ab16349), dilution 1:2,500. Imaging Kodak
films were scanned in the transmissive mode on a GS-710
Calibrated Imaging Densitometer from Bio-Rad using the
Quantity One software package. Each band was thereby
designated a value proportional to the protein concentra-
tion in the band. The quality of the antibody reactions was
evaluated on the basis of the Western blots where a single
strong band indicates a high-affinity specific antibody.
Several antibodies were found to give Western blots of
insufficient quality in our system either because reactions
were to weak or because of the presence of several bands
indicating that the antibody possesses low-affinity and/or
unspecific reactivity in the given system.
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